|hPD-L1-Fc||Unit size||Cat. code||Docs||Qty||Price|
Soluble human PD-L1 fused to an IgG1 Fc domain
Soluble human PD-L1 (CD274) fused to an IgG1 Fc domain
hPD-L1-Fc is a soluble human PD-L1 (CD274) fusion protein generated by fusing the N-terminal extracellular domain of human PD-L1 (aa 19-237) to the N-terminus of an engineered human IgG1 Fc domain with a 2 amino acid linker.
hPD-L1-Fc has an apparent molecular weight of ~66 kDa on an SDS‑PAGE gel.
hPD‑L1‑Fc is expressed in CHO cells and purified by protein G affinity chromatography.Back to the top
Applications: Flow cytometry, protein-protein interaction studies, T cell activation blocking (binding to hPD-1 expressed on T cells).
Formulation: 0.2 µm filtered solution in sodium phosphate buffer with glycine, saccharose and stabilizing agentsBack to the top
- 50 µg lyophilized hPD-L1-Fc.
- 1.5 ml endotoxin-free water.
Product is shipped at room temperature.
Store lyophilized product at -20°C.
Product is stable for at least 1 year.Back to the top
Programmed cell death ligand 1 (PD-L1), also known as B7 homolog 1 (B7-H1) and cluster of differentiation 274 (CD274), is a member of the B7 family of immunoregulatory proteins .
It is a transmembrane protein over‑expressed on tumor cells and tumor infiltrating immune cells, such as macrophages.
PD-L1 binds to programmed cell death protein 1 (PD-1; also known as CD279) on cytotoxic T cells, inhibiting the antitumor immune response [2,3].
Collins M. et al., 2005. The B7 family of immune-regulatory ligands. Genome Biol. 6(6):223.
McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.